PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy

Abstract

4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1. See related article by Peper-Gabriel et al., p. 3387.

CITA DEL ARTÍCULO Clin Cancer Res. 2022 Aug 2;28(15):3182-3184. doi: 10.1158/1078-0432.CCR-22-0541.